Rznomics Inc., a South Korea based biopharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RZ-001 intended for the treatment of patients with Hepatocellular carcinoma (HCC).
The ODD allows the product to receive seven years of marketing exclusivity upon product approval, exemption from user fee and tax credits. It is also expected to provide access to specialised regulatory assistance from the FDA's Office of Orphan Products Development (OOPD).
Seong-Wook Lee, Rznomics CEO and founder, said, 'This FDA Orphan Drug Designation further underlines the potential of our pipeline to expeditiously address the current unmet medical needs of patients with Hepatocellular Carcinoma.'
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI